« Life Sciences Industry Facing New Challenges with the FDA's Latest | Main | FDA Approvals - St. Jude Medical Announces FDA Approval Of Epic Stented Tissue »

FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug


FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia
The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone), a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.
 

©2006 FDA-News.com. All rights reserved.